Teleborsa: distribution and commercial use strictly prohibited

EMARKET SDIR

CERTIFIED



## COMPANY PRESENTATION

# 8<sup>th</sup> Annual Polytems Hir Italian Day in Frankfurt

January 24<sup>th</sup>, 2024



Member of Euronext Tech Leaders



EURONEXT

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.



Teleborsa: distribution and commercial use strictly prohibited

SDIR certified





1.0verview

2. Markets and Growth drivers

3. Our strategy and market approach

4. Financial Highlights

5.Current Outlook

6.Multiples & Comparables

Teleborsa: distribution and commercial use strictly prohibited EMARKET SDIR CERTIFIED



# **OVERVIEW**



## OVERVIEW

## A PRIMARY PLAYER PROVIDING MEDICAL, INDUSTRIAL AND CONSERVATION LASER SOLUTIONS WORLDWIDE



#### **World Class Hi-Tech company**

Hi-Tech industrial group providing laser solutions with proprietary technologies and know how developed over 40 years



Listed on Euronext STAR Milan of Italian Stock Exchange since year 2000 and member of Euronext Tech Leaders



#### Within Worldwide leaders in its space



Active worldwide on several laser application segments and markets...



...progressively widening its worldwide presence achieving continuous growth over the years

SDIR



## WE CREATE LIGHT, ENERGY, WAVES



#### **MEDICAL**

Our energy based systems improve people's well-being and life quality.

In the SURGICAL SECTOR, our minimally invasive technology systems minimize pain, side effects and risks of surgical procedures and hospitalization days.

In the AESTHETIC SECTOR, our systems satisfy the growing desire of individuals to improve their appearance also reducing pathological or painful imperfections.



**INDUSTRIAL** 

Our LASER CUTTING and MARKING SYSTEMS Improve the productivity of our customers manufacturing plants also limiting the environmental impact of manufacturing processes minimizing waste, fumes generated by the process, use of chemical additives, and allowing to eliminate the need for inks, solvents or glues within the process.



#### **CONSERVATION**

Our LASER SYSTEMS PRESERVE artworks of the universal heritage of our communities.



#### **ENVIRONMENT**



2 Photovoltaic systems active in 21

**4** New plants installed in 22



## **OUR HISTORY**

#### 

#### <u>80s</u>

Production of  $\mathrm{CO}_{\rm 2}$  lasers for dermatology, surgery and therapy

#### **1981**

Incorporation of El.En.S.n.c

#### <u>90s</u>

Development of short pulse Nd:YAG lasers for dentistry and minimally invasive surgery treatments

#### **○1990 - 1993**

Incorporation of **Deka MELA S.r.l., Lasit S.p.A.** e **Cutlite Penta S.r.l.** 

## <u>1998</u>

**Smartepil** (Deka Mela S.r.l.) - first long pulse Nd:Yag laser for dermatology and hair removal

#### <u>2000</u>

El.En.S.p.A. listed on the italian stock market

#### >2002

**Smartlipo** (Deka Mela S.r.l.**laserlipolisi**°: localized removal of adipose deposits with minimally invasive treatment

Acquisition of Cynosure Inc.

#### **2003**

Smartxide DOT<sup>\*</sup> Therapy (Deka Mela S.r.l.) dermatological surgery, anti-aging treatments, removal of pigmented lesions and scars

Acquisition of Asclepion GmbH

2004 Acquisition of Quanta System

#### 

Acquisition of Asa

Cynosure IPO on Nasdaq



Incorporation of a JV in China: Wuhan Penta Chutian Co.Ltd

Incorporation of Cutlite Do Brasil Alta Tecnologia Ltda

#### <u>2008 </u>

Mediostar XT (Asclepion GmbH) esthetics and hair removal.

Industrial sector El.En.– creation of the BLADE RF CO<sub>2</sub> **BLADE RF** laser sources family

Litho (Quanta System S.p.A.) surgical, treatment of kidney stones

## 2009

**Plus RF** (Cutlite Penta S.r.l.) with RF El.En. sources for metacrilate and wood cutting systems

Incorporation of Esthelogue S.r.l.

## 2010

**Smartxide**<sup>2</sup> (Deka Mela S.r.l.) laser system with CO<sub>2</sub> radio frequency (RF) laser sources for dermatological surgery and aesthetics

## 2011

Mediostar Next (Asclepion GmbH) aesthetics, hair removal



## **OUR HISTORY**

#### <u>2012</u>

Monna Lisa Touch<sup>™</sup> (Deka Mela S.r.l.) for the treatment of vaginal atrophy

**Cyber** (Quanta System S.p.A.) surgery, Lithotripsy and BPH

#### <u>2013</u>

Incorporation of second JV Penta Laser Equipment (Wenzhou) Co.Ltd

#### <u>2015</u>

**Bolt** (Penta Chutian e Wenzhou - China) enhanced system for laser metal cutting

**Discovery Pico** (Quanta System S.p.A.) tattoo and pigmented lesions removal and dermatological treatments

**HIROTT** (ASA S.r.l.) painful pathologies of the muscle and skeleton

Fiber Plus (Cutlite Penta S.r.l.) first metal cutting laser system equipped with fiber laser source

#### <u>2016</u>

Motus AX with Moveo (Deka Mela S.r.l.) hair removal, removal of pigmented lesions

Juliet<sup>®</sup> (Asclepion GmbH) for the treatment of vaginal atrophy

Deka M.E.L.A.S.r.l.and Quanta System S.p.A. join their commercial brand names into **Reinassance**° for the Italian market

## 

Industrial sector  ${\rm RF}~{\rm 1222}\,{\rm CO}_2\,{\rm RF}$  laser source "The Big Boy"

#### 

**ONDA Coolwaves**<sup>•</sup>(Deka Mela S.r.l.) the first microwaves technology system for body contouring

#### <u>2019</u>

The Chinese subsidiary Penta Laser Equipment (Wenzhou) Co. Ltd incorporates **Penta Laser Technology (Shangdong) Co. Ltd** 

Acquisition by Quanta System of Galli S.r.l. a precision mechanical components manufacturing facility.

## <u>2020</u>

Schwarzy (magnetotherapy) Red Touch (dermatology) Again (hair removal) Dr.Arnold (magnetotherapy)

#### 2021

Lasit Laser Polska incorporated by Lasit in Poland

Glide (dermatology) Chrome Laser Station (dermatology)

#### <u>2022</u>

Lasit Laser Iberica incorporated by Lasit in Spain

Acquisition by Penta Laser Zhejiang of **Shenzhen KBF Laser Tech Co. Ltd** 

## 2023


Lasit Laser Deutschland GmbH incorporated by Lasit in Germany


Lasit Laser UK Ltd incorporated by Lasit in UK

EMARKET SDIR certified



## EL.EN. WORLDWIDE





Teleborsa: distribution and commercial use strictly prohibited



## MARKETS AND GROWTH DRIVERS



## LASER SURGERY MARKET TRENDS

## **MINIMALLY INVASIVE SURGERIES:**

- Painless procedures
- Lower risks and side effects
- Shorter hospital stays/Faster recovery
- Savings by Private & National Health Systems
- Attractive ROI for surgical services providers
- Rapidly Growing Urology laser market






## MEDICAL AESTHETICS MARKET TRENDS

- Aging demographics and increasing focus on improving appearance and youthfulness;
- Growing interest in non-invasive or minimally invasive procedures and awareness of energybased aesthetic treatments
- Growing global obesity rate
- Reductions in procedure costs, attracting a broader patient base
- Normalization and social acceptance of cosmetic procedures
- Rapid growth expected





## MARKET RESEARCHES GROWTH ESTIMATES

#### **GLOBAL MEDICAL LASER MARKET**

- Mordor Intelligence
- Fortune business insights
- Global Market Insights
- Research and Markets

CAGR 13,4% to 2028 CAGR 13,1% to 2030 CAGR 14,5% to 2032 CAGR 13,2% to 2030

#### With an estimated market size of $\simeq$ \$5 Bln in 2021 including:

- Ophthalmology
- Dermatology
- Aesthetics
- Surgical
- Synecology Urology
- Cardiovascular
- Dentistry


#### **EXPECTED GROWTH IN COSMETIC MARKET**

- Research and Markets
- The business research company

CAGR 15,2% to 2027 CAGR 19,1% to 2027



SDIR certified






## INDUSTRIAL LASER MARKET TREND



## Laser cutting applications:

- Laser power increase + Cost reduction: enhanced flexibility, productivity and quality standards in manufacturing processes
- New application verticals
- Building and construction





- Products identification and traceability
- Minimal environmental impact

## Laser processing market:

- Size: \$17,48 billion in 2021
- Expected CAGR to 2030: 9,1%

Source: Grand view research

Teleborsa: distribution and commercial use strictly prohibited



## OUR STRATEGY AND MARKET APPROACH

## OUR KNOWLEDGE



## **Technical Knowledge**



| El | ectr | oni | ics |
|----|------|-----|-----|
|    |      |     |     |





Photonics

Mechanics



Fluid dynamics



Nower electronics

Sof







## **Application Expertise**

Aesthetics



Surgery



Dermatology



Physiotherapy




Cutting




Marking

Art Conservation

## THE LASER ADVANTAGE









Flexibility

- Speed
- Power
- Precision
- Selectivity
- Effectiveness



 Continuous investment in R&D: maintaining the unmatched wideness of our product range by innovating existing technologies and developing new ones

Cooperation with primary research institutions and KOL'S

Excellent knowledge of the target markets based on the widespread and loyal distribution network created over the years

Ability to continuously update the laser technology of our wide product range

Focus on innovative products release, technical support and continuous training to our customers

Multi brand approach

**ELEN**<sup>®</sup>



CERTIFIE

#### WIDE RANGE OF PRODUCTS IN MEDICAL SECTOR **ELEN**<sup>®</sup>




un volailaito d

EMARKET SDIR CERTIFIED

## .. AND IN INDUSTRIAL SECTOR

Cutting





## **Art Conservation**









distribution and some

## Marking

use strictly prohibited

EMARKET SDIR

CERTIFIED











**OUR PRODUCTS** 

**ELEN**<sup>®</sup>

atviath



Teleborsa: distribution and commercial use strictly prohibited



## FINANCIAL HIGHLIGHTS



## INCOME STATEMENT – FY 2022

**ELEN**<sup>\*\*</sup>

| Euro '000                  | 31/12/21 | %      | 31/12/22 | %      | Var. % |
|----------------------------|----------|--------|----------|--------|--------|
| Medical                    | 311.290  | 54,5%  | 382.063  | 56,7%  | 22,7%  |
| Industrial                 | 260.112  | 45,5%  | 291.518  | 43,3%  | 12,1%  |
| Revenues                   | 571.402  | 100,0% | 673.581  | 100,0% | 17,9%  |
| Gross margin               | 212.073  | 37,1%  | 249.695  | 37,1%  | 17,7%  |
| Operating Expenses         | 47.812   | 8,4%   | 56.250   | 8,4%   | 17,6%  |
| Staff espenses             | 84.170   | 14,7%  | 98.194   | 14,6%  | 16,7%  |
| EBITDA                     | 80.091   | 14,0%  | 95.251   | 14,1%  | 18,9%  |
| Depr., amort., accruals    | 15.234   | 2,7%   | 14.250   | 2,1%   | -6,5%  |
| EBIT                       | 64.858   | 11,4%  | 81.001   | 12,0%  | 24,9%  |
| Net financ.income(charges) | 1.752    | 0,3%   | (1.934)  | -0,3%  |        |
| Other income (expense) net | (185)    | 0,0%   | (79)     | 0,0%   | -57,5% |
| EBT                        | 66.424   | 11,6%  | 78.988   | 11,7%  | 18,9%  |
| Income taxes               | 17.300   | 3,0%   | 19.953   | 3,0%   | 15,3%  |
| Minorities                 | 3.688    | 0,6%   | 3.925    | 0,6%   | 6,4%   |
|                            | 45.436   | 8,0%   | 55.111   | 8,2%   | 21,3%  |
|                            | 73,730   | 0,070  |          | 0,270  | 22,370 |

## **BALANCE SHEET– FY 2022**

| Euro '000                     | 31/12/21 | 31/12/22 | Var.%  |
|-------------------------------|----------|----------|--------|
|                               |          | restated |        |
| Total non current assets      | 136.648  | 165.786  | 21,3%  |
| Net Working Capital           | 144.641  | 200.536  | 38,6%  |
| Other receivables/payables ST | (91.278) | (80.154) | -12,2% |
| Net financial position        | 115.766  | 75.363   | -34,9% |
| Long term liabilities         | 18.076   | 18.077   | 0,0%   |
| Net Equity                    | 287.701  | 343.455  | 19,4%  |
| Net capital employed          | 171.935  | 268.092  | 55,9%  |
| Net Working Capital on sales  | 25,3%    | 29,8%    |        |
| ROCE                          | 37,7%    | 30,2%    |        |
| (EBIT/Net capital employed)   |          |          |        |
| Operating Capex               | 23.150   | 28.514   |        |
|                               |          |          |        |


EMARKET SDIR certified


# Income Statement – 9M 2023

**ELEN**<sup>®</sup>


| Euro '000                  | 30/09/22  | %      | 30/09/23              | %            | Var. %   |
|----------------------------|-----------|--------|-----------------------|--------------|----------|
|                            | unaudited |        | unaudited             |              |          |
| Medical                    | 270.529   | 55,9%  | 287.954               | 58,4%        | 6,4%     |
| Industrial                 | 213.820   | 44,1%  | 205.057               | 41,6%        | -4,1%    |
| Revenues                   | 484.348   | 100,0% | 493.011               | 100,0%       | 1,8%     |
| Gross margin               | 179.496   | 37,1%  | 187.211               | 38,0%        | 4,3%     |
| <b>Operating Expenses</b>  | 41.511    | 8,6%   | 44.393                | 9,0%         | 6,9%     |
| Staff espenses             | 70.421    | 14,5%  | 80.938                | 16,4%        | 14,9%    |
| EBITDA                     | 67.564    | 13,9%  | 61.880                | 12,6%        | -8,4%    |
| Depr., amort., accruals    | 9.640     | 2,0%   | 10.102                | 2,0%         | 4,8%     |
| EBIT                       | 57.924    | 12,0%  | 51.778                | <b>10,5%</b> | -10,6%   |
| Net financ.income(charges) | (7)       | 0,0%   | (866)                 | -0,2%        | 13078,8% |
| Other income (expense) net | 3         | 0,0%   | (42)                  | 0,0%         |          |
| EBT                        | 57.920    | 12,0%  | 50.870                | 10,3%        | -12,2%   |
|                            | 31/12/22  |        | 30/09/23<br>unaudited |              |          |
| Net financial position     | 75.363    |        | 32.089                |              |          |
|                            |           |        |                       |              |          |

CERTIFIED






Q3




CERTIFIED


# **ELEN** Revenue breakdown by business



# Revenue breakdown by area

**ELEN**<sup>\*\*</sup>





EMARKET SDIR

CERTIFIED

Teleborsa: distribution and commercial use strictly prohibited



## CURRENT OUTLOOK





## Revenue 2023 > Revenue 2022



Teleborsa: distribution and commercial use strictly prohibited



## MULTIPLES & COMPARABLES



| Stockholder's Equity per share | 4,5     |          |
|--------------------------------|---------|----------|
| Price / Book Value Adj.        | 2,1     |          |
| EV /EBIT (90% EBIT)            | 11,2    |          |
| EV / Sales (90% Sales)         | 1,2     |          |
|                                |         |          |
| El.En. Market Cap.             | 748,5 @ | € 9,36   |
| Net financial position         | 32,1 @  | 30/09/23 |
| Financial investments m/l term | 23,6 @  | 30/09/23 |
| Enterprise Value               | 692,7   |          |



## COMPARABLES


| Sept. 30th , 2023  | _                |             |       |         |        |         |         |          |         |        |
|--------------------|------------------|-------------|-------|---------|--------|---------|---------|----------|---------|--------|
|                    | Price on Jan.19, | Revenue     | Var.% | EBIT    | EBIT % | МК.Сар. | EV      | EV/Sales | EV/EBIT | P/Book |
| Medical/Aesthetic  | 2024             |             | Rev.  |         |        |         |         | (*)      | (*)     | Value  |
| Cutera (2)         | \$3,03           | \$116       | -5%   | \$(53)  | -46%   | \$60    | \$267   | 1,1      | n.a.    | n.a.   |
| InMode             | \$22,90          | \$365       | 14%   | \$144   | 40%    | \$1.900 | \$1.227 | 2,5      | 6,4     | 2,6    |
| Beauty Health      | \$2,39           | \$301       | 13%   | \$(113) | -37%   | \$314   | \$506   | 1,3      | n.a.    | 3,5    |
| Venus              | \$1,35           | <b>\$58</b> | -23%  | \$(21)  | -36%   | \$7     | \$86    | 1,1      | n.a.    | n.a.   |
| Sisram Medical (2) | \$0,61           | \$172       | -2%   | \$22    | 13%    | \$285   | \$271   | 0,8      | 6,2     | 0,6    |
| Classys            | € 23,66          | € 94        | 25%   | € 48    | 51%    | € 1.532 | € 1.492 | 11,9     | 23,4    | 8,1    |
| Industrial         |                  |             |       |         |        |         |         |          |         |        |
| IPG Photonics Co.  | \$99,31          | \$989       | -10%  | \$203   | 21%    | \$4.660 | \$3.596 | 2,7      | 13,3    | 2,0    |
| Han's Laser        | ¥18,15           | ¥9.344      | -11%  | ¥599    | 6%     | ¥19.350 | ¥19.036 | 1,5      | 23,9    | 1,2    |
| Bystronic (2)      | CHF 437          | CHF 468     | 3%    | CHF 25  | 5%     | CHF 797 | CHF 410 | 0,4      | 8,1     | 1,1    |
| El.En. (1)         | € 9,36           | € 493       | 2%    | € 52    | 11%    | € 748   | € 693   | 1,2      | 11,2    | 2,1    |

(1) EV and multiplies as for previous slide

(2) Financials on June 30th, 2023

(\*) Revenue, Ebit and earnings annualized

CERTIFIED







#### CONTACTS

El.En. S.P.A. Enrico Romagnoli Investor Relations Manager tel. +39 055-8826807 E-mail: <u>finance@elen.it</u>

#### **POLYTEMS HIR**

*Financial Communication, IR and Press Office* **Bianca Fersini Mastelloni** - b.fersini@polytemshir.it **Silvia Marongiu** - <u>s.marongiu@polytemshir.it</u> Tel. +39 06-69923324